A new collaborative study from Chalmers University of Technology and Oslo University Hospital points to blood-based clues that could reveal Parkinson’s disease years, even decades, before visible symptoms. Researchers found patterns tied to DNA repair and cellular stress that appear early in the disease process and disappear once the condition progresses. Using machine learning to sift through gene activity, the team says these signals could make broad screening with blood tests feasible within a few years.
The study focused on early molecular changes rather than the later neurodegeneration everyone recognizes. In those early years the body ramps up DNA repair and stress responses in cells, and those changes leave detectable marks in blood. Detecting those marks could create a real chance to act before major brain damage takes hold.
Researchers trained machine learning models to pick out consistent gene activity patterns linked to those processes. The models flagged differences that were not present in healthy people or in patients already diagnosed with Parkinson’s. That suggests the signals point to the disease’s initial biology instead of its later-stage consequences.
Annikka Polster, who led the study, said the work exposes an “important window of opportunity” and framed the timing crisply: “before motor symptoms caused by nerve damage in the brain appear.” That window matters because by the time motor problems surface, much of the damage is already done. Finding the disease before that point changes the whole conversation about treatment timing.
“The fact that these patterns only show at an early stage and are no longer activated when the disease has progressed further also makes it interesting to focus on the mechanisms to find future treatments,” she added. The team believes that identifying the mechanisms now opens pathways to both new therapies and repurposing existing drugs. If gene activity mirrors disease mechanisms, drugs targeting those pathways could be tested much earlier.
Polster also noted that the biomarkers seen in blood “likely reflect some of the early biology of the disease,” and that this “paves the way for broad screening tests via blood samples: a cost-effective, easily accessible method.” Blood-based screening is appealing because it is scalable and less invasive than brain imaging or other procedures. Large-scale screening could help catch cases long before clinical diagnosis.
The authors published their findings in npj Parkinson’s Disease and emphasized plans to refine detection tools and probe how these mechanisms unfold. They anticipate that blood tests for early Parkinson’s could start appearing in clinical practice within about five years. Alongside diagnostics, the group is optimistic about identifying drug candidates that could halt or slow progression.
“If we can study the mechanisms as they happen, it could provide important keys to understanding how they can be stopped and which drugs might be effective,” Polster said. She went on to underline drug repurposing as a realistic avenue: “This may involve new drugs, but also drug repurposing, where we can use drugs developed for diseases other than Parkinson’s because the same gene activities or mechanisms are active.” That practical approach could speed treatments to patients.
The team was candid about limits. Gene activity in blood only partly mirrors what occurs in the brain, and medications or other external factors might have influenced results. The study population may also not represent every demographic, so broader validation is required before rolling out screening widely.
Parkinson’s affects millions worldwide and is on the rise, making earlier detection a major public health goal. Symptoms range from tremors and slowed movement to sleep problems, loss of smell, fatigue, mood changes, and cognitive slowing. Treatments today manage symptoms but do not cure the disease, which is why catching it earlier could change outcomes.
Danish Anwer, the study’s first author, distilled the urgency: “By the time the motor symptoms of Parkinson’s disease appear, 50% to 80% of the relevant brain cells are often already damaged or gone,” he said. That stark reality frames why research pushing detection into pre-symptomatic years could have real clinical impact.
Fox News senior medical analyst Dr. Marc Siegel echoed the concern about late detection, noting, “By the time you have actual motor symptoms affecting gait, tremor, etc., a large majority of affected cells have been damaged and destroyed,” he told Fox News Digital. He called the research “exciting,” and said it “opens the door for earlier and more effective diagnosis and treatment.”
